HQL: Dividend Can Be Sustained Through 2026

2026-01-28 02:38:10 ET

Overview

The abrdn Life Sciences Investors Fund ( HQL ) is structured as a closed-end fund that aims to provide attractive total returns through a portfolio of healthcare securities. What differentiates HQL from standard ETFs is the specific focus on income generation. When I previously covered HQL, I issued a buy rating due to the attractive valuation at the time. Since then, the fund has produced total returns that exceed the S&P 500. Since my last coverage, the fund has released an updated annual report for 2025, which prompted me to revisit the fund's overall value proposition for 2026....

Read the full article on Seeking Alpha

For further details see: